沪指4月24日上涨0.03%，申万所属行业中，今日上涨的有10个，涨幅居前的行业为美容护理、银行， 涨幅分别为1.61%、1.16%。医药生物行业今日上涨0.25%。跌幅居前的行业为计算机、通信，跌幅分别 为2.36%、2.08%。 主力资金净流出的行业有25个，电子行业主力资金净流出规模居首，全天净流出资金66.21亿元，其次 是计算机行业，净流出资金为64.60亿元，净流出资金较多的还有机械设备、通信、汽车等行业。 医药生物行业今日上涨0.25%，全天主力资金净流入2.65亿元，该行业所属的个股共476只，今日上涨的 有243只，涨停的有10只；下跌的有218只，跌停的有3只。以资金流向数据进行统计，该行业资金净流 入的个股有204只，其中，净流入资金超5000万元的有10只，净流入资金居首的是双成药业，今日净流 入资金1.81亿元，紧随其后的是凯莱英、金凯生科，净流入资金分别为1.63亿元、1.37亿元。医药生物 行业资金净流出个股中，资金净流出超3000万元的有9只，净流出资金居前的有花园生物、迈瑞医疗、 智飞生物，净流出资金分别为8240.77万元、6250.66万元、6132.45万元。（数据宝） ...

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-017 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、浙江花园生物医药股份有限公司（以下简称"公司"或"本公司"）2024 年度 权益分配采用派息比例不变的权益分派方法； 2、公司回购账户不存在库存股份； 3、本次权益分派期间，"花园转债"不停止转股。 一、股东会审议通过权益分派方案 公司于 2025 年 4 月 15 日召开 2024 年年度股东会，审议通过了《关于 2024 年度利 润分配方案的议案 》，2024 年年度股 东会决议公告已于 当日在巨潮资讯网 （www.cninfo.com.cn）上披露。 1、公司 2024 年年度股东会审议通过的权益分配方案为：向全体股东每 10 股派发 现金股利人民币 1.14 元（含税）。公司最终以实施 2024 年度利润分配方案时股权登 记日的公司总股本为基数 ...

根据《公司向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集说 明书》"）的规定，在本次发行之后，若公司发生派送股票股利、转增股本、增发新 股或配股、派送现金股利等情况（不包括因本次发行的可转债转股而增加股本的情形）， 则转股价格相应调整。具体的转股价格调整公式如下（保留小数点后两位，最后一位 四舍五入）： 派送股票股利或转增股本：P1=P0/（1+n）； | 证券代码：300401 | 证券简称：花园生物 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于可转换公司债券转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 一、关于"花园转债"转股价格调整的相关规定 经中国证券监督管理委员会"证监许可[2023]252 号"文同意注册的批复，浙江花 园生物医药股份有限公司（以下简称"公司"）于 2023 年 3 月 6 日向不特定对象发行 了 1,200 万张可转换公司债券，每张面值 100 元，发行总 ...

Core Points - The Shanghai Composite Index closed at 3296.36 points, below the six-month moving average, with a slight decline of -0.10% [1] - The total trading volume of A-shares reached 12,624.62 billion yuan [1] - A total of 176 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary of Stocks Exceeding Six-Month Moving Average - Stocks with the highest deviation rates include: - Jiyang Precision (13.55% deviation, latest price 22.22 yuan) [1] - Weimao Electronics (10.89% deviation, latest price 29.94 yuan) [1] - Sanmu Group (9.55% deviation, latest price 4.06 yuan) [1] - Other notable stocks with smaller deviation rates include: - David Medical (just above the six-month line) [1] - Ice Wheel Environment (just above the six-month line) [1] - Ningbo United (just above the six-month line) [1] Additional Stock Performance Data - The performance of several stocks on the day includes: - Dongbei Group (9.98% increase, latest price 5.62 yuan) [1] - Fenghua Co. (10.03% increase, latest price 13.05 yuan) [1] - Niuwei Co. (7.78% increase, latest price 26.33 yuan) [1] - The trading turnover rates for these stocks vary, with some exceeding 30% [1]

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Market Performance - On April 17, 2025, the pharmaceutical sector had a change of +0.04%, outperforming the CSI 300 index by 0.06 percentage points, ranking 16th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+0.98%), pharmaceutical distribution (+0.40%), and offline pharmacies (+0.35%) performed well, while other bioproducts (-0.57%), vaccines (-0.48%), and blood products (-0.22%) lagged [1] - Top three gainers in individual stocks were Kangpeng Technology (+20.00%), Nuosige (+10.06%), and Yisheng Pharmaceutical (+10.03%); top three losers were Changyao Holdings (-6.33%), Hasanlian (-5.26%), and Shouyao Holdings (-4.81%) [1] Industry News - On April 17, 2025, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved statistically significant positive results in a key Phase III clinical trial (ACHIEVE-1) [2] - The study evaluated the safety and efficacy of Orforglipron compared to a placebo in adults with type 2 diabetes who had poor blood sugar control through diet and exercise alone [2] - Orforglipron is a research-based, once-daily oral small molecule (non-peptide) GLP-1 receptor agonist that can be taken at any time of the day without food and drink restrictions [2] Company News - Huayuan Bio (300401) reported Q1 2025 revenue of 326 million yuan, a year-on-year decrease of 1.18%, with net profit attributable to the parent company at 97 million yuan, a year-on-year increase of 5.50%, and a non-recurring net profit of 88 million yuan, up 44.42% year-on-year [3] - Puluo Pharmaceutical (000739) reported Q1 2025 revenue of 2.73 billion yuan, a year-on-year decrease of 14.63%, with net profit attributable to the parent company at 249 million yuan, a year-on-year increase of 1.98%, and a non-recurring net profit of 206 million yuan, down 14.05% year-on-year [3] - Sanbo Brain Science (301293) reported 2024 revenue of 1.43 billion yuan, a year-on-year increase of 8.84%, with net profit attributable to the parent company at 105 million yuan, a year-on-year increase of 34.24%, and a non-recurring net profit of 94 million yuan, up 0.77% year-on-year [3] - Betta Pharmaceuticals (300558) reported 2024 revenue of 2.89 billion yuan, a year-on-year increase of 17.74%, with net profit attributable to the parent company at 403 million yuan, a year-on-year increase of 15.67%, and a non-recurring net profit of 410 million yuan, up 55.92% year-on-year [3]

Financial Performance - The company's operating revenue for Q1 2025 was ¥326,391,133.03, a decrease of 1.18% compared to ¥330,273,302.02 in the same period last year[6] - Net profit attributable to shareholders increased by 5.50% to ¥96,511,379.04 from ¥91,483,091.72 year-on-year[6] - The net profit after deducting non-recurring gains and losses surged by 44.42% to ¥88,138,393.32 compared to ¥61,030,303.01 in the previous year[6] - Total operating revenue for the current period was ¥326,391,133.03, a decrease of 1.7% from ¥330,273,302.02 in the previous period[22] - Net profit for the current period was ¥96,509,841.11, up 5.6% from ¥91,483,091.72 in the previous period[23] - Earnings per share increased to ¥0.18 from ¥0.17, indicating a growth of 5.9%[23] Cash Flow and Investments - The net cash flow from operating activities rose by 29.70% to ¥144,056,264.68 from ¥111,071,221.09 year-on-year[6] - Operating cash inflow for the current period was $390,437,025.51, slightly up from $388,596,451.91 in the previous period, indicating a growth of approximately 0.22%[25] - Cash outflow from investing activities decreased to $196,939,714.12 from $705,581,140.41, showing a reduction of approximately 72%[25] - Net cash flow from investing activities improved to -$196,939,714.12 from -$325,625,112.24, reflecting a 39.5% reduction in cash outflow[25] - The company’s cash flow from operating activities remains strong, with a net increase despite challenges in financing activities[25][26] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,536,546,355.58, a decrease of 1.36% from ¥5,612,645,527.96 at the end of the previous year[6] - Total liabilities decreased to ¥2,193,883,495.20 from ¥2,394,249,260.65, representing a reduction of approximately 8.4%[21] - Total equity attributable to shareholders increased to ¥3,342,668,208.44 from ¥3,218,400,077.44, reflecting a growth of about 3.9%[21] - The company's cash and cash equivalents decreased from CNY 1,284,473,292.97 to CNY 1,055,421,957.77, a decline of approximately 17.8%[19] - The company reported a total current asset of CNY 2,263,623,163.71, down from CNY 2,469,407,256.94, indicating a decrease of approximately 8.3%[19] Shareholder Information - Shareholders' equity attributable to the parent company increased by 3.86% to ¥3,342,668,208.44 from ¥3,218,400,077.44 at the end of the previous year[6] - The number of ordinary shareholders at the end of the reporting period was 27,868[15] Operational Efficiency - Total operating costs decreased to ¥225,274,384.48 from ¥260,819,419.20, reflecting a reduction of approximately 13.6%[22] - The company reported a significant reduction in financial expenses, which fell to ¥3,671,625.11 from ¥7,527,764.01, a decrease of about 51.2%[22] - Research and development expenses were ¥16,376,140.28, down from ¥20,557,191.99, a decrease of approximately 20.5%[22] Future Outlook - Future performance guidance remains optimistic, with expectations for improved financial metrics in the upcoming quarters[18] - The company is focusing on new product development and market expansion strategies, although specific details were not provided in the call[18] - The company has not disclosed any significant mergers or acquisitions during this reporting period[18]

花园生物：2025年第一季度净利润9651.14万元，同比增长5.50%。 ...

特别提示： 1、本次股东会无否决议案的情形； | 证券代码：300401 | 证券简称：花园生物 公告编号：2025-015 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 2、本次股东会不涉及变更前次股东会决议。 3、会议召开方式：采取现场投票与网络投票相结合的方式 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议召开时间：2025年4月15日（星期二）下午14:30。 网络投票时间：2025年4月15日。其中，通过深圳证券交易所交易系统进行网络投 票的时间为2025年4月15日上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳 证券交易所互联网投票系统进行投票的具体时间为2025年4月15日9:15-15:00的任意时 间。 2、现场会议地点：浙江省东阳市南马镇花园村花园大厦1号会议室。 4、会议召集人：公司董事会 5、现场会议主持人：公司董事长邵徐君先生 6 ...

北京浩天律师事务所 关于浙江花园生物医药股份有限公司 2024 年年度股东会 法律意见书 二〇二五年四月十五日 北京浩天律师事务所 浙江花园生物医药股份有限公司 2024 年年度股东会法律意见书 北 京 浩 天 律 师 事 务 所 Hylands Law Firm 北京市朝阳区东三环中路 5 号财富金融中心 12 层 12F Fortune Financial Center, No.5 Dongsanhuan Zhong Road, Chaoyang District, Beijing 100020, China 电话Tel：（86-10）65028888，传真Fax：（86-10）65028866 北京浩天律师事务所 关于浙江花园生物医药股份有限公司 2024 年年度股东会 法律意见书 致：浙江花园生物医药股份有限公司 北京浩天律师事务所接受浙江花园生物医药股份有限公司（以下简称"公司"） 委托，指派本所律师对公司 2024 年年度股东会（以下简称"本次股东会"）进 行法律见证，并依据《中华人民共和国证券法（2019 年修订）》(以下简称《证 券法》)、《中华人民共和国公司法（2023 年修订）》（以下简称 ...